




# **Department of Radiation Oncology**

# ASTRO Schedule of Presentations and Activities



**2017 Annual Meeting** 

September 24 - 27, 2017 San Diego Convention Center San Diego, California

# Saturday, September 23

10:00 AM - 5:15 PM

Rm 29 A/B/C/D

**ARRO Annual Seminar (INTERACTIVE)** 

10:15 am Global Health Scholar Presentation Puja Shweta Venkat, MD Shefali Gajjar, MD Steven Lau, MD, PhD

### Sunday, September 24

4:45 - 6:15 PM

Rm 30 A/B/C

**Joint Session 1** 

ASTRO-SITC Joint Session: Clinical Implications of New Findings on the Immunogenic Effects of Radiation (INTERACTIVE)

5:10 p.m.

Clinical Relevance of Recent Research for Prostate Cancer

William McBride, DSc, PhD

Poster Viewing Q&A 1: GU, Biology

1:15 - 2:45 PM

Presentation No: 2570 John Hegde, MD

Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-Free Survival in Intermediate- and High-Risk Prostate Cancer

Presentation No: 2593 Amar Kishan, MD

Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: Preliminary Toxicity Results of a Phase 2 Trial

Presentation No: 2628 Kiri Sandler, MD

Whole Pelvis Radiation Therapy Does Not Significantly Improve Prostate-Cancer Specific Survival in Patients With Gleason Score 9-10 Prostate Adenocarcinoma: An Analysis of 942 Patients Treated in the Modern Era 4:45 - 6:15 PM

Scientific Session 04

Lung 1 - SBRT

4:55 p.m. - Presentation No: 34

Results from a Prospective Phase 2 Trial Evaluating Safety and Efficacy of Combining Stereotactic Body Radiation Therapy with Radiofrequency Ablation for Centrally Located Lung Tumors

Percy Lee, MD

Posters - Hall C

Presentation No: 2629 Kiri Sandler, MD

Dramatic Polarization in Genitourinary Expert Opinions Regarding the Clinical Utility of Advanced Imaging Technologies in Prostate Cancer

Presentation No : 2664 Ye Yuan, MD, PhD

Testosterone Levels and Sexual Quality of Life Following Stereotactic Body Radiation Therapy for Prostate Cancer: A Multiinstitutional Analysis of Prospective Trials

# Monday, September 25

7:45 - 9:00 AM

Rm 5A

Scientific Session 08

HSR 1 - Health Care Costs

8:05 a.m. - Presentation No: 79

Cost-Effectiveness Analysis of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer

Eric Michael Chang, MD

7:45 - 9:00 AM Rm 5B

**Scientific Session 09** 

Patient Reported Outcomes

8:05 a.m. - Presentation No: 85

The Patient's Perspective on Breast Radiation Therapy: Initial Fears and Expectations Versus Reality

Narek Shaverdian, MD

10:45 - 12:15 PM

**Scientific Session 12** 

Head and Neck 1 - Chemoradiation for Head and Neck Can-

10:45 a.m. - Presentation No: 90

Functional Outcomes after De-escalated Chemoradiation For Human Papillomavirus-Positive Oropharyngeal Cancer: Findings from a Phase 2 Trial

John Hegde, MD

10:45 - 12:15 PM

Rm 6B

Rm 7A/B

Educational Session—14

<u>Translating Hypofractionation Trials in Prostate Cancer to</u>
Clinical Practice

11:45 a.m.

Treatment Planning and Delivery for Hypo-fractionated Stereotactic Body Radiotherapy

Nzhde Agazaryan, PhD, MS

Rm 8

# Monday, September 25, Cont'd

3:45 - 4:15 PM

Hall B2-G, Booth #3709

6:00 - 8:00 PM

**Gaslamp District** 

Meet the Expert Session - Lung Meet The Expert - Percy Lee, MD ASTRO Annual Alumni and Friends Reception and Gold Medal Celebration

The Whiskey House, 420 Third Ave, San Diego, CA

Poster Viewing Q&A 3: Breast, GYN, Nursing

10:45 - 12:15 PM

Presentation No: 2040 John Hegde, MD

Factors Associated With MRI Screening in Women With a Personal History of Invasive, Unilateral Breast Cancer Predominately Encompass Detectability Concerns Rather Than Future Breast Cancer Risk

Posters - Hall C

Posters - Hall C

Poster Viewing Q&A 4: Physics

4:15 - 5:45 PM

Presentation No: 3633 Steve Pai-hsun Lee, MD, PhD
Biologically Effective Dose-Volume Analysis for Patients Treated
with Moderately Hypofractionated IMRT for Unresectable Lung
Cancer

**Presentation No : 3695** Xiangrong (Sharon) Qi, PhD Fast, Low-Dose Megavoltage-Topogram Localization in a Helical IGRT Unit: Initial Clinical Experience with Mesothelioma Patients

Presentation No: 3744 Chenyang Wang, MD, PhD
Dose-Dependent Increase in Solid Tumor Heterogeneity Measured by the Standard Deviation of T2 Relaxation Time Constant

Presentation No: 3757 Kaley Woods, MS
Cochlea-Sparing Acoustic Neuroma Treatment with 4p Radiation
Therapy

Presentation No: 3766 Yingli Yang, PhD
Longitudinal Diffusion MRI for Early Assessment of Treatment
Response in Sarcoma Patients After Preoperative Radiation
Therapy

Presentation No: 3767 Youming Yang, PhD
Gold Nanoparticle Dose Enhancement of Inverse-Compton
Based Monoenergetic Photon Beams: A Monte Carlo Evaluation

# Tuesday, September 26

7:45 - 9:00 AM

Scientific Session 22

**Late-breaking Abstracts Special Session** 

7:54 a.m.

Presentation No: LBA-9

68Ga-PSMA PET/CT mapping of early biochemical recurrence (PSA <1 ng/mL) after primary surgery in 270 patients: Impact on Salvage Radiotherapy Planning

Nicholas George Nickols, MD, PhD

1:00 - 2:30 PM

Rm 2

Workshop 05

CROPS - Getting from the Bench to the Bedside: How to Translate Lab Findings into Clinical Trials

1:54 p.m.

How to design scientific end points in clinical trials **Joanne Weidhaas, MD, PhD** 

10:15 - 11:30 AM

Ballroom 20

Rm 5A

Awards Ceremony - ASTRO Gold Medal Michael Steinberg, MD

Poster Viewing Q&A 6: CNS, Head and Neck, Sarcoma

Posters - Hall C

2:45 - 4:15 PM

Presentation No: 2161 Audrey Dang, MD

Adjuvant and Salvage Radiation Therapy for Atypical Meningioma: A Retrospective Review of a Single Institution Experience at the University of California at Los Angeles from 1999-2015

Poster Viewing Q&A 7: GI, Hematologic 4:45 - 6:15 PM

Presentation No: 2395 Percy Lee, MD

Phase 1 Study of Stereotactic Body Radiation Therapy for Liver Tumors Utilizing an MRI-Guided Tri-Co Teletherapy System

Presentation No: 3792 Anusha Kalbasi, MD

5-Day Hypofractionated Preoperative Radiation Therapy in Soft Tissue Sarcoma: Preliminary Toxicity and Pathologic Outcomes from a Prospective Phase 2 Study

Posters - Hall C

Presentation No: 2469 Chenyang Wang, MD, PhD
Cancer-Specific Mortality of Right- Versus Left-Sided Colorectal
Adenocarcinoma: A Surveillance, Epidemiology, and End Results
Database Analysis

# Wednesday, September 27

11:00 - 12:30 PM

**Rm 1 A/B** 

Scientific Session 38

GU 3 - Emerging Outcomes for Aggressive Prostate Cancers Treated with Upfront Radiotherapy

11:10 a.m.

Presentation No: 282 Amar Kishan, MD
Extremely Dose Escalated Radiation Therapy Improves
Cancer- Specific Survival Compared With Radical
Prostatectomy or Conventionally Dose-Escalated Radiation
Therapy in Gleason Score 9-10 Prostate Adenocarcinoma:
A Multi-institutional Analysis of 1403 Patients

11:40 a.m.

Presentation No: 285 Kiri Sandler, MD
Clinical Outcomes for Patients With Gleason Score 10
Prostate Adenocarcinoma: Results From a Multi-I
institutional Consortium Study

12:00 p.m.

Presentation No: 287 Amar Kishan, MD Longer-Term Androgen Deprivation Therapy Improves Cancer- Specific Survival in Patients With Gleason Score 9 -10 Prostate Adenocarcinoma: An Individual Patient-Level Meta-analysis of RTOG 8531, 8610, and 9202

1:30 - 3:00 PM

Rm 1 A/B

**Scientific Session 41** 

GI 3 - Clinical Results of Esophagogastric and Hepatobiliary Cancers

2:40 p.m. - Presentation No: 313

Outcomes Utilizing MRI-Guided and Real-Time Adaptive Pancreas Stereotactic Body Radiotherapy (SBRT)

Naomi Jiang, MD

1:30 - 3:00 PM

Rm 30 D/E

Scientific Session 43

Lung 4 - Toxicity

1:50 p.m.

Presentation No: 325

Impact of Prior Radiation Therapy on the Efficacy and Toxicity of Pembrolizumab in the Treatment of Non–small Cell Lung Cancer

Narek Shaverdian, MD

2:50 p.m.

Discussants: Percy Lee, MD

3:15 - 4:45 PM

Rm 4

Scientific Session 47

Physics 9 - Outcome Analysis and Modeling 2

4:05 p.m.

Presentation No: 358 Xiangrong (Sharon) Qi, PhD
Dosimetric Predictors for Quality of Life After Prostate
Stereotactic Body Radiation Therapy via Deep Learning
Network

#### eP 16 - Physics ePoster Discussion 5 - Delivery Techniques

Rm 5B

1:30 - 3:00 PM

Discussants: Eric Klein, PhD, FASTRO

Daniel Low, PhD Eric Klein 2:24 p.m.

Presentation No: 1143 Youming Yang, PhD
Use of Pd-103 Significantly Enhances Shielding Effect of
Intraocular Silicone oil in Plaque Brachytherapy: GEANT4

Monte Carlo Simulations

**UCLA Radiation Oncology ASTRO News** 

Social Media: #UCLARadOnc and #ASTRO17

Email: radoncnews@mednet.ucla.edu